Bipolar Disorder – Current Treatment – Current Treatment: Physician Insights – Bipolar Disorder (EU5)
Bipolar disorder (BD) is a spectrum disorder characterized by recurrent episodes of aberrant mood; patients may exhibit manic, depressive, or mixed symptoms between periods of stable mood. Lithium, antiepileptic drugs (AEDs) such as lamotrigine, and atypical antipsychotics are the mainstay therapies used to manage BD; they may be prescribed alone or in combination. The availability of these long-standing staples in a highly genericized and price-conscious market poses a challenge to branded therapies entering the market. This situation is complicated by differences in drug availability across European countries, variations in patients’ symptom profiles and drug responses, and shortcomings of current therapies. Understanding physicians’ prescribing habits and decision points when treating BD, as well as anticipated changes in therapy choice as new options become available, enables manufacturers and developers to assess opportunities in this indication.
Questions answered
- What are the drivers and constraints influencing physicians’ treatment decisions for bipolar disorder?
- How are patients being treated in various lines of therapy, and what is the patient share of individual therapies?
- How do physicians manage the treatment of depressive and manic episodes in bipolar patients?
- What factors drive and constrain the use of key therapies?
- To what extent is polypharmacy used for bipolar disorder in different lines of therapy in Europe?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product description
Through survey data from EU5 physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:
- Understand the treatment landscape for a disease and how physicians make prescribing decisions.
- Evaluate the drivers and obstacles that influence treatment selection.
Geography: EU5 (France, Germany, Italy, Spain, and the United Kingdom).
Primary research: Survey of 251 EU5 psychiatrists
Key companies: Johnson & Johnson Innovative Medicine, Pfizer, AbbVie, Gedeon Richter
Key drugs: Lithium, AEDs, SSRIs, SNRIs, atypical antipsychotics
Key analyses
- Factors influencing disease management and treatment decisions
- Drivers and constraints of treatment selection
- Physician-reported treatment practices and brand-level patient shares
- Rationale for changes in treatment approach
- Physician insight on persistency and compliance
- Physician-reported recent / anticipated changes in brand usage or treatment approach
